Evaluation of CD71 Expression in Acute Leukemia in Egyptian Patients

Authors
Yasmin Nabil El-Sakhawy, Shaimaa Abdelmalik Pessar, Noha Hussein Boshnak
Ain Shams University Egypt
Corresponding Author
Yasmin Nabil El-Sakhawy
Email: yasminnabil@hotmail.com, Mobile: 1005276531

Abstract

Background: CD71 or transferrin receptor is an integral membrane protein that mediates cellular iron uptake. It has been identified as a proliferation marker being expressed on many solid tumours as well as hematological neoplasms. Hence, CD 71 expression was assessed as a flow cytometric marker for leukemia and lymphoproliferative neoplasms. However, only few studies aimed to address its diagnostic and prognostic implications as well as its relation to clinical and laboratory markers. So, our study aimed at evaluation of the significance of CD71 (transferrin receptor 1, TFR-1) as a flow cytometric marker for the diagnosis of acute leukemia (AL).

Methods: Seventy two patients diagnosed as acute leukemia; fifty six acute myeloid leukemia (AML) and sixteen Precursor B acute lymphoblastic leukemia (pre B ALL) were enrolled in the study and assessed for CD71 expression on blast cells by flow cytometry.

Results: CD71 expression was found to be significantly higher in acute myeloid leukemias than precursor B lymphoblastic leukemia (p:0.000) while median of MFI of CD71 was significantly higher in B lymphoblastic leukemia (p:0.016) than acute myeloid leukemia with the most remarkable expression was on poorly differentiated AML FAB subtypes.

Conclusion: CD71 may be useful for the differential diagnosis of precursor B-ALL from AML in addition it could be useful in the evaluation of differentiation stage in case of AML.

Key Words: CD71, Transferrin receptor, Acute Leukemia, Poorly differentiated AML, Precursor B ALL.

Introduction
Acute leukemias either lymphoblastic or myeloid represent heterogeneous groups of neoplastic disorders with high morbidity and mortality rates along with heterogeneity in survival and prognosis [1,2].

Flow cytometric immunophenotyping has important role in acute leukemia. It is mandatory for the diagnosis of all cases of ALL, minimally differentiated AML and mixed phenotype acute leukemia. Also, immunophenotyping pattern help guiding genetic studies specific for this phenotype. As aberrant expression is frequently encountered, a battery of antibodies is required for definitive characterization of blast lineage [3].

Despite advances in classification, management strategies and prognostic tools, Extensive research is still needed for better understanding of evolution of acute leukemia, improve stratification, and better outcome.

The transferrin receptor (CD71) is an integral membrane protein that mediates the uptake of
transferrin-iron complexes\[^4\]. Two transferrin receptors have been cloned (TfR1 and TfR2); however, TfR1 is considered the major protein responsible for iron uptake owing to its higher affinity and expression pattern \[^5\]. CD71 is a homodimeric glycoprotein containing 760 amino acids, which binds to diferric transferrin at the cell surface. This makes iron available for heme synthesis and for many metabolic processes necessary for cell growth and proliferation, including DNA synthesis, electron transport, nitrogen fixation and oxygen sensing \[^4,6\].

The expression of transferrin receptor is widespread; hepatocytes, endocrine pancreas, placental syncytiotrophoblasts, myocytes, spermatocytes, basal keratinocytes and erythroid precursors \[^6\]. The highest expression presents on early erythroid precursors through the intermediate normoblast phase, after which expression decreases through the reticulocyte phase \[^7-9\].

CD71 overexpression has been reported in many neoplasms, including solid tumors such as lung \[^10,11\], bladder \[^12\], colon \[^13\], pancreas \[^14\] and breast cancer \[^15,16\], gliomas \[^17\] as well as hematological malignancies \[^18-20\].

Higher expression of CD71 has been identified as a negative prognostic marker for numerous solid tumor types \[^14,16\] as well as for non-Hodgkin’s lymphoma \[^21-24\]. The high consumption of iron by the proliferating cells to act as co-factor for ribonucleotide reductase which is necessary for DNA synthesis makes the basis of targeting CD71 as an experimental anticancer therapy \[^25\].

There is still very little information on the possible importance of CD71 in acute leukemias, and the data that is available is conflicting \[^22,26,27\].

Our aim from this study is to evaluate the significance of CD71 (transferrin receptor 1, TfR-1) as a flow cytometric marker for the diagnosis of acute leukemia (AL).

**Subjects and Methods**

This study conducted on 72 patients (40 males and 32 females and age range 1-74 years) newly diagnosed as acute leukemia based on their morphology following French-American-British classification and immunophenotype in central Hematology Lab, Ain Shams University Hospital after consent from them or their guardians to use their samples in this study. They were exposed to the following laboratory investigations:

- Complete history taking and thorough clinical examination with special account on pallor, purpura, organomegaly and lymphadenopathy.
- 2 ml on K\(_2\)EDTA tube for complete blood count including differential white blood cells count on a Sysmex XE 2100 analyser with Leishman stained peripheral blood smear.

**Bone marrow aspiration:**

- Morphologic assessment and blast count.
- Myeloperoxidase stain.
- Immunophenotyping using our routine panel for acute leukemia and with measurement of CD71 expression on multiparameter flow cytometry (Coulter Epics XL flow cytometry, Coulter Corporation, Miami, FL, USA) using monoclonal Abs of Becton Dickinson Biosciences (BD Biosciences, San Jose, CA).

Fresh bone marrow cells were prepared by red blood cell lysing solution, and incubated with Fluorochrome conjugated monoclonal antibodies at the concentrations recommended by the manufacturer. The antibody combinations used are listed below:

1) CD45, CD34, FITC Neg/PE Neg control 1.
2) CD45, CD34, CD15, CD117.
3) CD45, CD34, CD7, CD33.
4) CD45, CD34, HLA-DR, CD13.
5) CD45, CD34, CD14, CD64.
6) CD45, CD34, FITC Neg/PE Neg control 2.
7) CD45, CD34, CD2,CD19.
8) CD45, CD34, CD20,CD10.
9) CD45, CD34, CD38, CD56.
10) CD45, CD34, HLA-DR, CD71.
11) CD45, CD34, cytTdT, cytCD79a.
12) CD45, CD34, cytMPO, cytCD3.

Positivity level was determined based on a fluorochrome-conjugated isotypic Ig control.
A minimum of 100,000 cells were recorded per sample. Data were analyzed with C: XL ACL&089, Run time protocol. Threshold gating of bone marrow mononuclear cells (BMMNC) was assigned based on forward scatter (FSC) and side scatter (SSC) to exclude red blood cells, dead cells and cell debris. A CD45/SSC scatter gram allowed gating BMMNC to define cell subsets for further immunophenotyping.

The percentage of CD71+ve cells and the mean fluorescent intensity (MFI) of CD71 on the gated cell populations were determined in comparison to the isotype control.

**Statistical analysis:**
Data were collected and entered to the Statistical Package for Social Science (IBM SPSS) version 20. Qualitative data were presented as number and percentages while quantitative data were presented as mean, standard deviations, ranges, medians with interquartile ranges (IQR). The comparison between groups regarding qualitative data were done by using Chi-square test while comparison between two group with quantitative data and parametric distribution were done by using Independent t-test and with non parametric distribution were done by using Mann-Whitney test. Also comparison between more than two groups regarding quantitative data with non parametric distribution were done by using Kruskall-Wallis test. Spearman correlation coefficients were used to assess the correlation between two quantitative parameters in the same group. The confidence interval was set to 95% and p-value was considered non significant at the level of > 0.05 (NS), significant at the level of > 0.05 (S) and highly significant at the level of < 0.01 (HS).

**Results**
About 72 individuals recently diagnosed with acute leukemia were enrolled in the study with their median age 33.5 yrs, IQR (11.5-50) yrs and range (1-74) yrs, with male to female ratio 1.2/1.

Distribution of hematological parameters, blast count and CD71 expression is demonstrated in table 1.

**Table (1): Distribution of hematological parameters, blast count and CD71 expression:**

| Parameter   | Median (IQR) | Range       |
|-------------|--------------|-------------|
| CD71        | 45.7 (14.6 – 79.75) | 0.89 – 97.4 |
| MFI         | 2.2 (1.6 – 5.8)   | 1.1 – 29.1  |
| TLC         | 19 (7.95 – 51.85) | 1 – 216     |
| Hb          | 7.75 (6.65 – 9)   | 4.2 – 12.5  |
| Plt         | 24 (13.5 – 56)    | 7 – 192     |
| Blast count | 74.5 (57.5 – 83.5) | 20 – 97     |

CD71 was found to be heterogenously expressed in acute leukemia cases with median 45.7%, IQR: (14.6 – 79.75) and range (0.89 – 97.4). MFI of CD71 with median 2.2, IQR: (1.6 – 5.8), and range (1.1 – 29.1) (figure 1).

**Figure (1): Median CD71 expression and MFI in both AML and pre B-ALL**

Cases of acute leukemia comprised: 56/72 (77.8%) of cases were acute myeloid leukemia and 16/72 (22.2%) of cases were precursor B-acute lymphoblastic leukemia (table 2).
Table (2): The frequency of each leukemia type in our study:

| Type              | No. | %  |
|-------------------|-----|----|
| M0                | 1   | 1.4|
| M1                | 9   | 12.5|
| M2                | 14  | 19.4|
| M3                | 8   | 11.1|
| M4                | 10  | 13.9|
| M5                | 9   | 12.5|
| M7                | 5   | 6.9 |
| Precursor B       | 16  | 22.2|
| Total             | 72  | 100|

As expected, lymphadenopathy was significantly higher in Precursor B-ALL than in myeloid leukemia while hepatosplenomegaly showed no significant difference between myeloid and lymphoid leukemias (table 3).’

Table (3): Comparison between myeloid group and lymphoid group regarding organomegaly and LDN:

|                  | Myeloid group | Precursor B group | Chi-square test |
|------------------|---------------|-------------------|-----------------|
|                  | No. | %  | No. | %  | X²  | P-value|
| Liver            |     |    |     |    |     |        |
| Negative         | 25  | 44.6% | 6  | 37.5% | 0.259 | 0.611|
| Positive         | 31  | 55.4% | 10 | 62.5% |
| Spleen           |     |    |     |    |     |        |
| Negative         | 23  | 41.1% | 4  | 25.0% | 1.371 | 0.242|
| Positive         | 33  | 58.9% | 12 | 75.0% |
| LN               |     |    |     |    |     |        |
| Negative         | 35  | 62.5% | 5  | 31.2% | 4.922 | 0.027|
| Positive         | 21  | 37.5% | 11 | 68.8% |

Table (4): Comparison between myeloid and precursor B groups regarding the studied parameters:

|                  | Myeloid group | Precursor B group | Mann-Whitney test |
|------------------|---------------|-------------------|-------------------|
|                  | Median (IQR)  | Median (IQR)      | Z       | P-value|
| Age              | 37 (25.5 – 52)| 8 (4 – 22.5)      | -3.198  | 0.001|
| CD71             | 55.1 (27.9 – 81.8)| 3.87 (2.13 – 13.96)| -4.558  | 0.000|
| MFI              | 2.1 (1.5 – 3.5)| 4.5 (1.9 – 13.8) | -2.404  | 0.016|
| TLC              | 20.5 (10.5 – 60.95)| 10.2 (6.7 – 19.35)| -2.195  | 0.028|
| Hb               | 8.02 ± 1.73 | 7.45 ± 1.76       | 1.163   | 0.249|
| Plt              | 28 (18 – 65) | 20.5 (10.5 – 42) | 1.356   | 0.175|
| Blast count      | 65.16 ± 19.02| 80.94±14.50       | 3.067   | 0.003|

CD71 expression was found to be significantly higher in acute myeloid leukemias than precursor B lymphoblastic leukemia (p:0.000) while median of MFI of CD71 was significantly higher in precursor B lymphoblastic leukemia than acute myeloid leukemia (0.016). Total leukocytic count was significantly higher in AML than pre B-ALL while blast count was significantly higher in pre B-ALL than AML. The percentage of blast cells in BM samples varied from 20 to 96 with Mean±SD 65.16 ± 19.02 in the AML group while in ALL was 42 to 97 with Mean±SD 80.94±14.5 (table 4).

Table (5): Comparison between myeloid and precursor B groups regarding the studied parameters:

|                  | Myeloid group | Precursor B group | Z       | P-value|
|------------------|---------------|-------------------|---------|--------|
|                  | Median (IQR)  | Median (IQR)      |         |        |
| Age              |               |                   | -3.198  | 0.001 |
| CD71             |               |                   | -4.558  | 0.000 |
| MFI              |               |                   | -2.404  | 0.016 |
| TLC              |               |                   | -2.195  | 0.028 |
| Hb               |               |                   | 1.163   | 0.249 |
| Plt              |               |                   | 1.356   | 0.175 |
| Blast count      |               |                   | 3.067   | 0.003 |

When correlating CD71 expression and MFI with age, immunophenotypic markers, hematological parameters and blast count: a significant positive correlation was found between CD71 expression and each of age, common myeloid markers; CD13, CD33,CD117 and a significant negative correlation with CD14 and HLA-DR and common lymphoid markers; CD10, CD19, CD20,
CD5. A significant negative correlation was found between mean fluorescence intensity of CD71 expression and each of age, TLC, CD13 and CD14 and a significant positive correlation with common lymphoid markers; CD10, CD19, CD20 (table 5 and figures 2&3).

**Table (5): Correlation of CD71 and MFI with the studied parameters:**

|        | CD71  | MFI   |
|--------|-------|-------|
|        | r     | p-value | r     | p-value |
| CD71   | 0.015 | 0.902  | 0.015 | 0.902  |
| MFI    | 0.015 | 0.902  | 0.015 | 0.902  |
| Age    | 0.360** | 0.002 | -0.228 | 0.054 |
| CD13   | 0.300* | 0.013 | -0.327** | 0.007 |
| CD33   | 0.243* | 0.048 | -0.231 | 0.061 |
| CD117  | 0.333** | 0.066 | -0.156 | 0.208 |
| CD14   | -0.281* | 0.021 | -0.274* | 0.025 |
| CD19   | -0.334** | 0.066 | 0.248* | 0.043 |
| CD20   | -0.247* | 0.044 | 0.322** | 0.008 |
| CD2    | -0.061 | 0.626  | -0.005 | 0.966 |
| CD5    | -0.260* | 0.033 | 0.149  | 0.229 |
| CD7    | -0.021 | 0.869  | -0.176 | 0.154 |
| CD34   | 0.040  | 0.750  | 0.114  | 0.357 |
| HLADR  | -0.249* | 0.042 | -0.116 | 0.351 |
| CD10   | -0.391** | 0.001 | 0.259* | 0.034 |
| TLC    | -0.108 | 0.368  | -0.517** | 0.000 |
| Hb     | 0.083  | 0.489  | 0.000  | 0.997 |
| Plt    | 0.103  | 0.390  | -0.087 | 0.466 |
| Blast count | -0.096 | 0.424 | 0.044 | 0.714 |

**Fig (2):** CD71 expression positively correlates with CD117 and negatively correlates with CD10.

**Fig (3):** CD71 MFI negatively correlates with CD13 and positively correlates with CD10.
When comparing both CD71 expression and MFI between various leukemia subtypes, we found that the highest CD71 expression was for M7>M0>M3>M1>M2>M4>M5>>>Precursor B-ALL while MFI was the highest in M7>Precursor B-ALL> M2,M3>M0>M1>M4>M5 (table 6 and figures 4&5).

**Table (6):** Comparison between different leukemia subtypes regarding both CD71 expression and MFI:

| Type           | CD71 Median (IQR) | MFI Median (IQR) |
|----------------|-------------------|------------------|
| Precursor B    | 3.87 (2.13 – 13.96) | 4.5 (1.9 – 13.8) |
| M0             | 82.9 (82.9 – 82.9)  | 2.3 (2.3 – 2.3)  |
| M1             | 78.5 (48.3 – 83.2)  | 2 (1.9 – 2.6)    |
| M2             | 53.05 (44.2 – 69.2) | 2.6 (1.4 – 3.5)  |
| M3             | 81.15 (49.55 – 86.25) | 2.6 (2.1 – 5)    |
| M4             | 41.6 (22.5 – 46.5)  | 1.8 (1.2 – 2.9)  |
| M5             | 19.5 (13.6 – 25.7)  | 1.3 (1.3 – 1.8)  |
| M7             | 88 (83.8 – 90)      | 15 (12.5 – 17.2) |
| X²             | 10.448             | 7.623            |
| P-value        | 0.000              | 0.000            |

**Fig 4:** Pattern of CD71 expression among studied leukemia subtypes.

**Fig 5:** Pattern of CD71 MFI among studied leukemia subtypes.

**Discussion**

There is a relation between antigens expressed by the tumor and its proliferation; and so, it is sensible to explore the correlation of the pattern of antigen expression with tumor behavior and treatment prognosis. CD71, the tranferrin receptor, is mandatory for iron transport into cells which is necessary for growth and proliferation,
hence, its wide distribution on both normal tissues with high dividing potential i.e. hematopoietic cells and malignant tissues, with the latter showing even higher expression.

In many studies [6,18,20-23,26-32], CD71 was found not only to be expressed by the majority of acute leukemias, chronic granulocytic leukemias in blast crisis, myeloma and lymphoproliferative disorders with variable density expression but also correlates with clinical data, morphologic subtypes, disease course and overall prognosis. Our study aimed at evaluation of CD71 expression in acute leukemia.

We found that CD71 expression was significantly higher in acute myeloid leukemias than precursor B lymphoblastic leukemia while mean fluorescence intensity (MFI) of CD71 was significantly higher in precursor B lymphoblastic leukemia than acute myeloid leukemia. Similar to Liu et al [28] who studied CD71 expression in Chinese population and found that CD71 may be useful for the differential diagnosis of B-ALL from AML. Also Pande et al. [33] found that the Majority of AMLs showed positivity for CD71, being positive in 84% of the cases while The CD71 positivity rate was only 30% in cases of B-ALL.

Liu et al [28] found that acute megakaryocytic leukemia cases expressed CD71 on leukemic cells the highest, with the mean±SD of expression percentage was 80.16±8.23% (IQR: 74.27%-92.33%, median 77.03%) and that of MFI was 14.61±6.31 (IQR: 9.09-23.65, median 12.84) similar to our median and IQR 88 (83.8 – 90) and MFI 15 (12.5– 17.2).

Also, in our study, the mean±SD of CD71 expression percentage and MFI of poorly differentiated myeloid leukemias (M0, M1, M2, M4) were 55.17±23.97 and 2.77±1.91 respectively. These results are near to those by Liu et al [28] which were 39.14±26.37% for expression percentage and 9.9±11.9 for MFI.

Regarding partially differentiated AML: Acute promyelocytic leukemia (APL) in our study had high CD 71% expression and MFI 81.15 (49.55 – 86.25) 2.6 (2.1 – 5) respectively in contrast to Liu et al [28] and AMoL in our study had low CD 71% expression and MFI 19.5 (13.6 – 25.7), 1.3 (1.3 – 1.8) respectively similar to Liu et al [28].

Acute lymphoblastic leukemias in our study were all of precursor B type with low % expression 3.87 (2.13 – 13.96) and MFI 4.5 (1.9 – 13.8), similar to Liu et al [28] who found B- ALL had % expression 9.63±9.77% (0.47%-39.23%, median 7.49%), with the MFIR of 1.93±1.1 (1.13-6.8, median 6.8).

These results were in contrast to El-Menshawy et al. [34] who studied CD71 expression in Egyptian population and demonstrated that CD71 is over expressed in ALL rather than AML.

When comparing different FAB subtypes of AML with each other regarding expression percentage and MFI, we found that the highest CD71 % expression was for M7 then poorly differentiated AML (M0, M1, M2, M4) then partially differentiated AML while precursor B-ALL was negative for this marker despite being of higher fluorescence intensity than AML similar to results by Liu et al [28] except for AML M3 which despite being partially differentiated however showed higher expression than most of poorly differentiated AML.

However, in contrast to El-Menshawy et al.[34] who found that there was an increased expression of CD71 in AML, M3, M4, and M5, partially differentiated myeloid leukemia with little maturation evidence along with high proliferation capacity.

The difference between our results and that of Menshawy et al. [34] may be due to reliance of the latter on MFI as a measure of antigenic expression.

Both Park et al. [35] and Liu et al. [28] also demonstrate that acute erythroblastic leukemia (AEL) patients do not necessarily express CD71 on their leukemic cells (including myeloblasts and erythroblasts) i.e. CD71 is not a specific and/or reliable marker for AEL. Koehler et al. [27] and Płoszyńska et al. [36] studied CD71 expression on ALLs and found more frequent expression of CD71 on T-ALLs than on B-ALLs. We were unable to observe CD71 expression on AEL and
T-ALLs because no such cases were included in our study.

In our study, a significant positive correlation was found between CD71 expression and each of age, common myeloid markers; CD13, CD33, CD117 and a significant negative correlation with CD14 and HLA-DR and common lymphoid markers; CD10, CD19, CD20, CD5. A significant negative correlation was found between mean fluorescence intensity of CD71 and each of age, TLC, CD13 and CD14 and a significant positive correlation with common lymphoid markers; CD10, CD19, CD20 while showed no significant correlation with any of clinicopathologic features.

These results were in comparison to El-Menshawy et al. [34] who found CD71 expression to correlate positively with total leukocyte count in ALL patients and negatively with platelet count in AML cases and Das Gupta et al. [22] in his study at an Indian population where no significant correlation with Hb or platelet count could be found but a significant negative correlation with platelet count in AML was found, and Kollia et al. [37] who concluded in his molecular analysis of CD71 mRNA expression in AML that no statistically significant correlation were found with specific FAB classification.

In conclusion, we suggest CD71 to be useful in differentiation of acute myeloid leukemia from precursor B ALL and further help in discriminating the differentiation status of AML. However, further prospective studies are needed to document possible relation of CD71 with response to treatment and relapse rate. Also, studies relate CD71 with clonal evolution in leukemia may predict possibility to be an important molecular target in future therapy of acute leukemia.

References

1. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant JP, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lheritier V, Fiere D (2004). Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 22(20):4075–4086.

2. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. (2008) Hematol Am Soc Hematol Educ Program 1–11.

3. Arber DA. Algorithmic approach to the classification of acute leukemia: United States & Canadian Academy of Pathology (USCAP) Web site. http://www.uscap.org/site/98th/pdf/companion21h02.pdf. Accessed June 4, 2010.

4. Aisen P. Transferrin receptor 1. Int J Biochem Cell Biol. 2004; 36:2137–2143.

5. Sargent PJ, Farnaud S, Evans RW. Structure/function overview of proteins involved in iron storage and transport. Curr Med Chem. 2005;12:2683–2693.

6. Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol. 1999;31:1111–1137.

7. Sieff C, Bicknell D, Caine G, et al. Changes in cell surface antigen expression during hematopoietic differentiation. Blood. 1982;60:703–713.

8. Lesley J, Hyman R, Schulte R, et al. Expression of transferrin receptor on murine hematopoietic progenitors. Cell Immunol. 1984;83:14–25.

9. Nakahata T, Okumura N. Cell surface antigen expression in human erythroid progenitors: erythroid and megakaryocytic markers. Leuk Lymphoma. 1994;13:401–409.

10. Kondo K, Noguchi M, Mukai K et al. Transferrin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis. Chest. 1990;97:1367–1371.

11. Zborovskaya I, Gasparian A, Kitaeva M et al. Simultaneous detection of genetic and immunological markers in non-small cell lung cancer: prediction of metastatic
12. Seymour GJ, Walsh MD, Lavin MF, Strutton G, Gardiner RA. Transferrin receptor expression by human bladder transitional cell carcinomas. Urol Res. 1987;15:341–344.

13. Prutki M, Poljak-Bhazi M, Jakopovic M, Tomas D, Stipancic I, Zarkovic N. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett. 2006;238:188–196.

14. Ryschich E, Huszty G, Knaebel HP, Hartel M, Buchler MW, Schmidt J. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer. 2004;40:1418–1422.

15. Shindelman JE, Ortmeyer AE, Sussman HH. Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer. 1981;27:329–334.

16. Habashy HO, Powe DG, Staka CG et al. Transferrin receptor (cd71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat. 2010;119:283–293.

17. Recht L, Torres CO, Smith TW, Raso V, Griffin TW. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg. 1990;72:941–945.

18. Barnett D, Wilson GA, Lawrence AC, Buckley GA. Transferrin receptor expression in the leukemias and lymphoproliferative disorders. Clin Lab Haematol. 1987;9:361–370.

19. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol. 1983;36:539–545.

20. Taetle R, Ralph S, Smedsru S, Trowbridge I. Regulation of transferrin receptor expression in myeloid leukemia cells. Blood. 1987;70:852–859.

21. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006;121:144–158.

22. Das Gupta A, Patil J, Shah VI. Transferrin receptor expression by blast cells in acute lymphoblastic leukemia correlates with white cell count & immunophenotype. Indian J Med Res. 1996;104:226–233.

23. Habeshaw JA, Lister TA, Stansfeld AG, Greaves MF. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet. 1983;1:498–501.

24. Brooks D, Taylor C, Dos SB et al. Phase Ia trial of murine immunoglobulin a antitransferrin receptor antibody 42/6. Clin Cancer Res. 1995;1:1259–1265.

25. Yu Y, Kovacevic Z, Richardson DR (2007) Tuning cell cycle regulation with an iron key. Cell Cycle 6(16):1982–1994.

26. Glasova M, Konikova E, Stasakova J, Babusikova O. The relationship of HLA-DR, CD38 and CD71 markers to activation, proliferation and differentiation of some human leukemia and lymphoma cells. Neoplasma. 1998;45:88–95.

27. Koehler M, Behm F, Hancock M, Pui CH. Expression of activation antigens cd38 and cd71 is not clinically important in childhood acute lymphoblastic leukemia. Leukemia. 1993;7:41–45.

28. Qian Liu, Mangju Wang, Yang Hu, Haizhou Xing, Xue Chen, Ying Zhang, Ping Zhu. The signifi cance of CD71 Expression by Flow Cytometry in the Diagnosis of Acute Leukemia. Leukemia & Lymphoma. 2014 Apr;55(4):892-8.

29. Chang-Jing G. Yeha, Colin G. Taylorb, W. Page Faulka. Transferrin Binding by Peripheral Blood Mononuclear Cells in Human Lymphomas, Myelomas and Leukemias. Vox Sang. 1984; 46: 217-223.
30. Loisel S, Andre PA, Golay J, Buchegger F, Kadouche J, Cerutti M, Bologna L, Kosinski M, Viertl D, Delaloye AB, Berthou C, Mach JP, Boumsell L. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia. Mol Cancer 2011; 10:42.

31. Moura IC, Lepelletier Y, Arnulf B, England P, Baude C, Beaumont C, Bazarbachi A, Benhamou M, Monteiro RC, Hermine O (2004) A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 103(5):1838–1845.

32. Wei YY, Zhang XZ, Zhang F, Li ZB, Wang NN, Liu S, Yue BH. Expression of CD71 on cell proliferation in hematologic malignancy and its correlation with Ki-67. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2015); 23(1):234–240.

33. Pande A, Dorwal P, Jain D, Tyagi N, Mehra S, Sachdev R, Raina V (2016): Expression of CD71 by flow cytometry in acute leukemias: More often seen in acute myeloid leukemia. Indian journal of pathology and microbiology 59(3):310–313.

34. Nadia El-Menshawy, Sherin M. Abd-Aziz, Mohammed A. Ebrahim, Nader El-Malky. Impact of cellular CD71 (transferrin receptor 1) expression in Egyptian acute leukemia: correlation with clinicopathologic features. Comp Clin Pathol. Published online 20 January 2016. DOI 10.1007/s00580-015-2213-x.

35. Park S, Picard F, Dreyfus F. Erythroleukemia: a need for a new definition. Leukemia 2002;16(8):1399-1401.

36. Płoszyńska A, Ruckemann-Dziurdzińska K, Jóźwik A, et al. Cytometric evaluation of transferrin receptor 1 (CD71) in childhood acute lymphoblastic leukemia. Folia Histochemica et Cytobiologica 2012;50(2):304–311.

37. Kollia P, Stavroyianni N, Stamatopoulos K, Zoi K, Viniou N, Mantzourani M, Noguchi CT, Paterakis G, Abazis D, Pangalos C, Loukopoulos D, Yataganas X (2001) Molecular analysis of transferrin receptor mRNA expression in acute myeloid leukaemia. Br J Haematol 115(1):19–24.